Pacific Biosciences of California  

(Public, NASDAQ:PACB)   Watch this stock  
Find more results for PACB
+0.68 (12.48%)
Oct 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.05 - 6.15
52 week 3.58 - 8.78
Open 5.19
Vol / Avg. 11.02M/1.54M
Mkt cap 459.56M
P/E     -
Div/yield     -
EPS -0.82
Shares 74.97M
Beta 2.48
Inst. own 70%
Dec 2, 2015
Pacific Biosciences of California Inc at ISI Medtools Conference Add to calendar
Oct 12, 2015
Q3 2015 Pacific Biosciences of California Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Oct 1, 2015
Pacific Biosciences of California Inc Launches New Sequencing Platform Based on Its SMRT Technology - Webcast
Sep 16, 2015
Pacific Biosciences of California Inc at Morgan Stanley Healthcare Conference
Aug 5, 2015
Q2 2015 Pacific Biosciences of California Inc Earnings Call - Webcast
Aug 5, 2015
Q2 2015 Pacific Biosciences of California Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -47.86% -109.19%
Operating margin -45.54% -103.73%
EBITD margin - -96.76%
Return on average assets -47.12% -50.75%
Return on average equity -128.85% -106.60%
Employees 344 -
CDP Score - -


1380 Willow Rd.
United States - Map
+1-650-5218000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Pacific Biosciences of California Inc. designs, develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Company's Single Molecule, Real-Time (SMRT) technology, its products enable de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company introduced the PacBio RS II System to address many of the limitations.

Officers and directors

Michael W. Hunkapiller Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 66
Bio & Compensation  - Reuters
Susan K. Barnes Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Age: 61
Bio & Compensation  - Reuters
Kevin P. Corcoran Senior Vice President - Market Development
Age: 52
Bio & Compensation  - Reuters
Michael Phillips Senior Vice President - Research and Development
Age: 64
Bio & Compensation  - Reuters
William Ericson Lead Independent Director
Age: 56
Bio & Compensation  - Reuters
David Botstein Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Brook H. Byers Ph.D Independent Director
Age: 68
Bio & Compensation  - Reuters
Randy Livingston Independent Director
Age: 61
Bio & Compensation  - Reuters
John F. Milligan Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters